Artivila Biopharma Announces First Patient Dosed in Phase II Clinical Trial of ARD-885 for Moderate-to-Severe Active Rheumatoid Arthritis
Artivila
Innovative Drug Developer
2026Year6Month30Day, Artivila (Artivila Biopharma) officially announced that its developed1Novel DrugARD-885For moderate to severe active rheumatoid arthritis (RA) ofIIThe Phase clinical trial has recently successfully completed the first subject dosing. This study is a randomized, double-blind, placebo-controlled, multicenter clinical study aimed at evaluatingARD-885Efficacy and Safety for the Treatment of Patients with Moderate to Severe Active Rheumatoid ArthritisThis is the drug's subsequentIA significant milestone achieved following the successful completion of Phase I clinical trials, marking the formal entry of this novel mechanism-of-action drug into the stage of clinical efficacy verification.
Novel Dual-Target Inhibition Mechanism,
Targeting RA and Broader Autoimmune Indications
ARD-885is currently the fastest-advancing dual-targeting therapy in global clinical developmentIRAK4andIRAK1Novel Dual-Target Small Molecule Drug for Autoimmune Diseases。IRAK4andIRAK1YesTLR/IL-1RMediatedNF-κBKey Nodes in Inflammatory Signaling Pathways,ARD-885By simultaneously inhibitingIRAK4andIRAK1, thereby achieving more thorough blockade of inflammatory pathways and holding promise for superior clinical efficacy.
IPhase clinical data show that,ARD-885Demonstrated good safety and tolerability in subjects, with no adverse events of Grade 2 or higher occurring (AE) or any serious adverse event(SAE)Pharmacokinetics (PK) Data showed good in vivo exposure and dose linearity for the drug; pharmacodynamics (PD) Data indicate that the drug can significantly inhibit the release of multiple inflammatory factors. The above results provide a basis for conductingARD-885ofIIThe Phase I clinical study laid a solid research foundation.
Rheumatoid arthritis (RA) is one of the common autoimmune diseases in China, with more than500tens of thousands of patients, there is a huge unmet clinical need. In addition toRAIn addition, Artivila also plans toARD-885its indications are gradually expanding to cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), atopic dermatitis (AD) and other autoimmune diseases.
Artivila
Artivila was founded in2018Artivila is an innovative drug R&D company dedicated to improving patients’ lives through its AI-driven drug discovery engine. Co-founded by Dr. Zhu Zhendong, a computational chemistry expert, and Dr. Niu Deqiang, a medicinal chemistry expert, both with over two decades of industry experience, Artivila is a global leader inAIDriving innovative drug R&D companies. Its unique “AI+HI”(Artificial Intelligence+Human Intelligence) Dual-Wheel Drive Model, Through ModularizationAIBy combining its R&D platform with extensive drug development expertise, the company has efficiently and cost-effectively established a product pipeline that balances innovation with commercial potential. The company focuses on three high-value therapeutic areas: autoimmune diseases, neurodegenerative diseases, and malignant tumors, dedicated to developingFIC（First-in-Class) andBIC（Best-in-Class) medications, changing patients' destinies.
Selected Successful Transactions by Kaicheng Capital
Biopharmaceuticals:Xiantong MedicineTongrui BiopharmaNeurite MedicalKangleyiweiHaichuang PharmaceuticalLuzhu BiologicsTongyuan Kang MedicineXuanzhu BiopharmaHuiSheng BiopharmaNeuoscience PharmaceuticalsHuajian FuturePrecursor DerivativesAndu BiopharmaVimoo BioJinlan GeneticsQiyu BiologicsChangxi PharmaQingpu BiotechHeyuan BiotechSuiKun IntelligenceNuowei BiotechHongyun BiologicsKangpu BioTianchen BiologicsBioSinoZedmanYinuo PharmaZhitai BiopharmaEnze TaikangArthur PharmaRuiZhou BiotechYoujia BiopharmaSaiyuan BiotechBoyin BiologicsZhongyin TechnologyProgen BiotechPuxin BiologicsHuaten PharmaceuticalBainuoWujiahe Gene
Biomanufacturing&Agri-Food Technology:JunhemengMethuselah Qingke BiotechHuasai BiotechJunji BiotechZhihe BiotechChengyuan BioMeibo BiotechDejin BiotechBai Kuirui BiotechRongrui TechnologyYanwei TechJinghai WeixiangHuahao ZhongtianBoruidiQihe BiotechGrainonDingchi BiologicsHuapai BiopharmaZhongnong Seed SourceLanmei Co., Ltd.ArticrystalJoyvio FreshJoyvio BlueberriesJiaweida BiopharmaTangneng TechnologySaino BiologicsGreen Kangcheng
